Better Medicines Faster Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over …

18 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Deep Learning A.I. A.I. - Machine Learning

Unlocking the Hidden Chemistry of Microbiomes for Next-Generation Therapeutics with ISMM • Expanding Customer Pipelines Biosortia Pharmaceuticals is pioneering a revolutionary approach in drug discovery through its Industrial Scale Microbiome Mining (ISMM) technology. By accessing the vast, untapped chemical diversity found within natural microbiomes, We unlock a hidden world of small molecules that play crucial roles in cellular signaling and disease processes. These small molecules, often referred to as the "drug-like dark matter" of cellular biology, have been largely inaccessible until now. Our technology allows for the large-scale harvesting and exploration of these compounds, providing an unprecedented opportunity to discover …

69 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Data Analytics Synthetic Biology Generative A.I. A.I. - Machine Learning

Rational design of new molecules and medicines, enabled by the fusion of artificial intelligence and structural biology. Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. We're hiring! https://boards.greenhouse.io/atomai

22 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology Generative A.I.

Scale Drug Discovery with Quantum-inspired Physics and AI AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases, such as immuno-oncology. Our unique approach leverages quantum-inspired physics algorithms to power generative AI in designing novel drug candidates—without relying on experimental data. We already delivered several drug discovery successes within our internal pipeline and through collaborations with pharmaceutical companies. Our most advanced programs are currently in vivo optimization. AQEMIA is based in Paris and London. We are growing and hiring! Check our …

32 similar entities Tags: FrenchTech120 FrenchTech2030 Type: Startup Activities: deeptech healthtech Technologies: A.I. Generative A.I. Synthetic Biology

Transforming Drug Target Discovery with Physics-Based dataset-free genAI Partnerships At NEBULA, we revolutionize drug discovery by providing a comprehensive, physics-based dataset-free genAI solution for mapping the full range of therapeutic target conformations. Unlike traditional drug development focused on small molecule screening, our innovative approach delves deep into the dynamic nature of macromolecular targets—proteins, mRNA, antigens—unveiling their multitude of physiological conformations. Our dataset-free technology integrates generative genAI with molecular dynamics, rooted in physical principles, to generate an exhaustive profile of potential target structures without relying on pre-existing data. By enhancing the understanding of drug targets, we empower pharmaceutical and biotech companies …

57 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. Generative A.I.

Anything is Druggable - with Quantum Accuracy Qubit Pharmaceuticals brings unparalleled accuracy and precision to drug discovery and design, using quantum physics to develop life-changing treatments for major diseases. We leverage our technologies and expertise to advance 7 fully owned drug discovery programs focusing on cancer resistance and escapement, a growing concern in aging populations, and chronic inflammatory diseases. We also co-develop programs with academia and pharmaceutical partners. Our proprietary ATLAS drug discovery platform unites our technologies based on 30 years of research from renowned scientists and founders, Louis Lagardère (Sorbonne University and CNRS), Matthieu Montes (CNAM), Jean-Philip Piquemal (Sorbonne …

70 similar entities Tags: FrenchTech2030 Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering the Future of Drug Discovery Through Quantum Innovation At BEIT, we push the boundaries of quantum and classical computing to solve the toughest challenges in drug discovery and beyond. Our advanced products—BDocker, BQChem, WaferMol, and more—deliver unparalleled speed, accuracy, and scalability for molecular docking, quantum chemistry, and high-throughput simulations. BDocker leverages state-of-the-art simulated annealing to outperform traditional docking tools, while BQChem utilizes GPU-accelerated, size-consistent Brillouin-Wigner perturbation theory for faster and more accurate quantum chemistry calculations. WaferMol expands capabilities even further with wafer-scale molecular dynamics, enabling rapid drug candidate screening and optimization for complex molecular systems. By collaborating with leading …

Type: Startup Activities: deeptech it services Technologies: A.I.

Unravelling complex biology with optogenetics, chemistry and computation for small molecule discovery. Our platform is built around a proprietary synthetic biology toolkit, featuring advanced optogenetic tools that enable precise temporal and spatial control of complex pathways and difficult-to-drug targets. Powered by vast proprietary datasets and cutting-edge AI models, our platform accelerates drug discovery and facilitates the generation of novel chemical matter, unlocking solutions for even the most challenging biological systems. biotechnology, aging, drug discovery, machine learning, synthetic biology, optogenetics, artificial intelligence, small molecule, rejuvenation, molecular biology, and novel therapeutics

203 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. Synthetic Biology A.I. - Machine Learning

Advanced integration of biological systems, math models and artificial intelligence The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and …

113 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceuticals of tomorrow. Vitroprobe Analytics performs biomolecular analysis at the atomic scale to help design the pharmaceutical drugs of tomorrow. The development of new effective pharmaceutical drugs to fight disease is a slow and expensive process. Successful drug design relies on a profound understanding of the interactions between drug candidates and their target molecules in the body. The company has developed a unique platform to analyze target molecular structure in3D with simultaneous identification of individual constituent atoms. With the novel patented technique drug targets can be examined …

21 similar entities Type: Startup Activities: biotech deeptech Technologies: Data Analytics

Mine enhanced chemical space. Design superior candidates Quantum-Mechanics and Machine Learning Drug Discovery. Pharmacelera develops proprietary Computer-Aided Drug Design software and provides access to its technology through flexible licensing options and computational chemistry services. The methodology mines an unexploited chemical space, finding starting points with larger chemical diversity and improving the creativity of chemists. The technology is based on accurate Quantum-Mechanics algorithms, Machine Learning and High-Performance Computing (HPC) and it derives from more than 25 years of research. Pharmacelera helps companies in Target Identification, Hit-Identification, Hit-to-Lead and Lead Optimization drug discovery stages by finding novel hits, improving ligand binding properties …

22 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. - Machine Learning A.I.

Navigating Biology, Discovering Drugs Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. We use the models to simulate biological processes in order to identify viable drug targets and discover new biology. The company is building a pipeline of first-in-class drug discovery programmes based on the identified targets.

86 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology A.I. A.I. - Machine Learning

Drug discovery with cutting-edge AI technology We’re pioneering the use of AI and shaping the future in drug discovery, significantly cutting costs and development times. Our unique AI algorithms have generated novel drug candidates and identified enhancements for existing therapies more efficiently than traditional methods, setting us apart in the competitive landscape. Artificial Intelligence, Data Science, Health, Medicines, and Drug development

146 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Unlocking a bold new world of transformative drug discovery InVirtuoLabs is a new-generation laboratory for drug discovery. We design novel drugs by combining advanced machine learning techniques with physics-based simulations to rapidly identify and optimize promising drug candidates.

87 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Synthetic Biology